Innovative Low-Cost SARS-CoV-2 Diagnostic Test Using Cell-Free Protein Synthesis ID: 2020-026
A groundbreaking diagnostic test for SARS-CoV-2 that promises rapid, accurate, and affordable results using a novel RNA switch mechanism.
Technology Overview
This research proposal outlines the development of a low-cost, paper-based diagnostic test for SARS-CoV-2, leveraging advanced cell-free protein synthesis technology. The test is designed to be simple and rapid, suitable for both home and point-of-care settings, without the need for sophisticated lab equipment. At its core, the technology utilizes a novel RNA switch mechanism, derived from pseudoknots, for the highly selective and specific detection of the virus's RNA. This system aims to achieve significant signal amplification without PCR, enabling detection sensitivity at an unprecedented level.
Key Advantages
- Highly affordable at $0
- 10 per test, enabling widespread use
- Simple and rapid detection suitable for home use or point-of-care settings
- Eliminates the need for PCR amplification, simplifying the testing process
Problems Addressed
- Addresses the urgent need for mass testing in the COVID-19 pandemic, especially for asymptomatic carriers
- Reduces the reliance on expensive, lab-based diagnostic equipment and processes
- Overcomes the limitations of current diagnostic tests, such as lower sensitivity and specificity
Market Applications
- Point-of-care diagnostics in clinics and hospitals
- Home-based testing for individuals
- Mass screening in public spaces and for large events
- Monitoring and controlling the spread of COVID-19, particularly in resource-limited settings
Additional Information
Technology ID: 2020-026
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report